300347 泰格醫藥
按盤價 
57.050 +3.220 (+5.982%)
57.050 +3.220 (+5.982%) | 2025/12 - 人民幣(K¥) | 變動 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 6,832,801 | 3.48% | 7,384,039 | 7,085,471 | 5,213,538 | 3,192,279 | |
| 減：營業總成本 | 6,312,645 | 12.52% | 5,554,125 | 5,156,544 | 3,637,765 | 2,420,862 | |
| 其中:營業成本 | 4,959,606 | 13.72% | 4,535,511 | 4,277,008 | 2,942,883 | 1,678,036 | |
| 財務費用 | 99,902 | 162.44% | (108,324) | (158,124) | (216,363) | 88,052 | |
| 資產減值損失 | (38,961) | -3,205.59% | (29,725) | (2,416) | (12,915) | 5,414 | |
| 公允價值變動收益 | 42,256 | -108.42% | 352,771 | 535,857 | 1,815,390 | 1,137,889 | |
| 投資收益 | 433,816 | 160.33% | 338,175 | 102,751 | 312,283 | 283,773 | |
| 其中：對聯營企業和合營企業的投資收益 | 198,507 | 534.80% | 105,183 | 39,763 | 14,348 | (3,508) | |
| 營業利潤 | 1,009,420 | 51.93% | 2,486,941 | 2,582,399 | 3,696,967 | 2,222,312 | |
| 利潤總額 | 1,003,215 | 50.98% | 2,488,533 | 2,585,377 | 3,684,566 | 2,218,707 | |
| 減：所得稅費用 | 198,159 | -8.53% | 338,606 | 313,652 | 292,864 | 189,707 | |
| 淨利潤 | 805,056 | 79.77% | 2,149,927 | 2,271,725 | 3,391,702 | 2,029,001 | |
| 減：非控股權益 | (82,834) | -294.05% | 125,077 | 265,173 | 517,539 | 279,226 | |
| 股東淨利潤 | 887,890 | 119.15% | 2,024,850 | 2,006,552 | 2,874,163 | 1,749,775 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 1.040 | 121.28% | 2.340 | 2.320 | 3.310 | 2.200 | |
| 每股派息 (元) * | 0.126 | -58.00% | 0.568 | 0.550 | 0.500 | 0.300 | |
| 每股淨資產 (元) * | 24.342 | 1.86% | 24.102 | 22.447 | 20.774 | 18.474 | |
| 審計意見 # | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 01/04/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
